Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up

Cancer Gene Therapy

Volumn 19, Issue 12, 2012, Pages 852-861

  Finocchiaro, L M E ^a   Glikin, G C ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

DMRIE; GM CSF; HSV TK; IL 2; lipofection; melanoma vaccine

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MELANOMA VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GENE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CANINE MELANOMA; CONTROLLED STUDY; DISEASE FREE INTERVAL; DISTANT METASTASIS; DOG DISEASE; FEMALE; FOLLOW UP; MALE; MELANOMA; METASTASIS FREE SURVIVAL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; SUICIDE GENE THERAPY; TREATMENT OUTCOME;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CRICETINAE; CYTOKINES; DISEASE-FREE SURVIVAL; DOG DISEASES; DOGS; FEMALE; FOLLOW-UP STUDIES; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-2; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA;

SIMPLEXVIRUS;

EID: 84869239561     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.72     Document Type: Article

References (35)

1. Hansen K, Khanna C. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer 2004; 40: 858-880. (Pubitemid 38519765)
2. Modiano JF, Breen M, Lana SL, Ehrhart N, Fosmire SP, Thomas R et al. Naturally occurring translational models for development of cancer gene therapy. Gene Ther Mol Biol 2006; 10: 31-40. (Pubitemid 351976175)
3. Ramos-Vara JA, Beissenherz ME, Miller MA, Johnson GC, Pace LW, Fard A et al. Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. Vet Pathol 2000; 37: 597-608.
4. Smith SH, Goldschmidt MH, McManus PM. A comparative review of melanocytic neoplasms. Vet Pathol 2002; 39: 651-678.
5. Finocchiaro LME, Glikin GC. Cancer gene therapy in large animals. In: Gustafsson WB (ed) New Gene Therapy and Cancer Research. Nova Science Publishers: New York, 2008, pp 279-292.
6. Quintin-Colonna F, Devauchelle P, Fradelizi D, Mourot B, Faure T, Kourilsky P et al. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2. Gene Ther 1996; 3: 1104-1112. (Pubitemid 27036114)
7. Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Keller ET et al. Development of human granulocyte-macrophage colony-stimulating factortransfected tumor cell vaccines for the treatment of spontaneous canine cancer. Hum Gene Ther 1998; 9: 1851-1861. (Pubitemid 28439091)
8. Alexander AN, Huelsmeyer MK, Mitzey A, Dubielzig RR, Kurzman ID, Macewen EG et al. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol Immunother 2006; 55: 433-442. (Pubitemid 43076895)
9. Dow SW, Elmslie RE, Willson AP, Roche L, Gorman C, Potter TA. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest 1998; 101: 2406-2414. (Pubitemid 28270435)
10. Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003; 9: 1284-1290. (Pubitemid 36418378)
11. Manley CA, Leibman NF, Wolchok JD, Riviè re IC, Bartido S, Craft DM et al. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. J Vet Intern Med 2011; 25: 94-99.
12. Bianco SR, Sun J, Fosmire SP, Hance K, Padilla ML, Ritt MG et al. Enhancing antimelanoma immune responses through apoptosis. Cancer Gene Ther 2003; 10: 726-736. (Pubitemid 37129460)
13. Reed SD, Fulmer A, Buckholz J, Zhang B, Cutrera J, Shiomitsu K et al. Bleomycin/interleukin-12 electrochemogene therapy for treating naturally occurring spontaneous neoplasms in dogs. Cancer Gene Ther 2010; 17: 457-464.
14. von Euler H, Sadeghi A, Carlsson B, Rivera P, Loskog A, Segall T et al. Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma. J Immunother 2008; 31: 377-384. (Pubitemid 351595160)
15. Glikin GC, Finocchiaro LME. Gene therapy for canine cancer: clinical results. In: Andrade RL, Batista CI (eds) Canine Behavior, Classification and Diseases. Nova Science Publishers: New York, 2012, pp 37-56.
16. Finocchiaro LME, Glikin GC. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma. Gene Ther 2008; 15: 267-276. (Pubitemid 351223463)
17. Grosenbaugh DA, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res 2011; 72: 1631-1638.
18. Finocchiaro LME, Villaverde MS, Gil Cardeza ML, Riveros MD, Glikin GC. Cytokineenhanced vaccine and interferon-b plus suicide gene as combined therapy for spontaneous canine sarcomas. Res Vet Sci 2011; 91: 230-234.
19. Finocchiaro LME, Spector A, Rossi UA, Gil-Cardeza ML, Sua?rez JL, Riveros MD et al. The potential of suicide plus immune gene therapy for treating osteosarcoma: the experience on canine veterinary patients. In: Butler EJ (ed) Sarcoma: Symptoms, Causes and Treatments. Nova Science Publishers: New York, 2012, pp 107-122.
20. Finocchiaro LME, Fiszman GL, Karara AL, Glikin GC. Suicide gene and cytokines combined non viral gene therapy for spontaneous canine melanoma. Cancer Gene Ther 2008; 15: 165-172. (Pubitemid 351240664)
21. San H, Yang ZY, Pompili VJ, Jaffe ML, Plautz GE, Xu L et al. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum Gene Ther 1993; 4: 781-788. (Pubitemid 24305772)
22. Gao X, Huang L. Cationic liposome-mediated gene transfer. Gene Ther 1995; 2: 710-722. (Pubitemid 26043284)
23. Moher D, Hopewell S, Schulz KF, Montori V, Gzsche PC, Devereaux PJ et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c869.
24. VCOG. Veterinary Co-operative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004; 2: 195-213.
25. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000; 60: 3989-3999. (Pubitemid 30636571)
26. Li S, Wilkinson M, Xia X, David M, Xu L, Purkel-Sutton A et al. Induction of IFNregulated factors and antitumoral surveillance by transfected placebo plasmid DNA. Mol Ther 2005; 11: 112-119. (Pubitemid 40012005)
27. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997; 3: 849-854. (Pubitemid 27353443)
28. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380-384. (Pubitemid 32467048)
29. Rochlitz C, Dreno B, Jantscheff P, Cavalli F, Squiban P, Acres B et al. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Cancer Gene Ther 2002; 9: 289-295. (Pubitemid 34205504)
30. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 2002; 188: 147-154. (Pubitemid 35398872)
31. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocytemacrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998; 95: 13141-13146.
32. Pan PY, Li Y, Li Q, Gu P, Martinet O, Thung S et al. In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery. Cancer Immunol Immunother 2004; 53: 17-25. (Pubitemid 38161177)
33. van Putten EH, Dirven CM, van den Bent MJ, Lamfers ML. Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma. Future Oncol 2010; 6: 1691-1710.
34. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
35. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.